EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats



Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats



Faseb Journal 20(14): 2594-2596



Pulmonary hypertension (PH) is a life-threatening disorder with high mortality rates and limited treatment options. Gene therapy is an alternative treatment strategy, yet viral vectors have inherent disadvantages including immune activation. The Sleeping Beauty (SB) transposon is a nonviral method of gene delivery that overcomes some of these drawbacks. A SB-based transposon harboring a constitutively active endothelial nitric oxide synthase (eNOS) gene was administered to Sprague-Dawley rats via tail vein injection using the carrier polyethylenimine. Two days after transposon delivery, monocrotaline (MCT) was administered to induce PH. Hemodynamic, histological, and molecular measurements were performed four weeks later. Animals coinjected with transposase showed a significant reduction in pulmonary arterial pressure (PABP, 31.67 +/- 6.03 mmHg, P < 0.01), an attenuation of right ventricle (RV) to whole heart (WH) wt ratios (0.227 +/- 0.0252, P < 0.05) and a decrease in the pulmonary vessel wall thickness index (36.87%, P < 0.001), compared with those animals receiving the eNOS transposon and a nonfunctional transposase (PABP 44.33 +/- 4.04 mmHg; RV/WH ratio 0.280 +/- 0.01; wall thickness index 62.14%) or control animals receiving MCT injection alone (PABP 49.67 +/- 3.22 mmHg; RV/WH ratio 0.290 +/- 0.0265; wall thickness index 71.99%). The physiological improvements correlated with therapeutic gene expression, suggesting that transposon-based genetic approaches have utility in the treatment of PH.

(PDF emailed within 0-6 h: $19.90)

Accession: 033411474

Download citation: RISBibTeXText

PMID: 17065228

DOI: 10.1096/fj.06-6254fje



Related references

Genistein attenuates monocrotaline-induced pulmonary arterial hypertension in rats by activating PI3K/Akt/eNOS signaling. Histology and Histopathology 32(1): 35-41, 2016

Change in eNOS gene expression and functional eNOS activity in pulmonary artery isolated from the monocrotaline-induced pulmonary hypertensive rats. Japanese Journal of Pharmacology 79(SUPPL 1): 127P, 1998

Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. European Journal of Pharmacology 666(1-3): 165-172, 2011

Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circulation Research 96(4): 442-450, 2005

Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Human Gene Therapy 15(12): 1270-1278, 2005

Adenovirus-mediated gene transfer of heme oxygenase-1 ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 104(17 Supplement): II 446, October 23, 2001

Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats. International Immunopharmacology 16(1): 7-16, 2013

A cysteine precursor attenuates monocrotaline-induced pulmonary hypertension in rats. FASEB Journal 13(5 PART 2): A827, March 15, 1999

Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Circulation Journal 73(9): 1722-1730, 2009

Quercetin attenuates the progression of monocrotaline-induced pulmonary hypertension in rats. Journal of Biomedical Research 26(2): 98-102, 2013

Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats. International Journal of Cardiology 221(): 587-596, 2016

Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats. Journal of Cardiovascular Pharmacology 65(6): 562-570, 2016

Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Cardiovascular Revascularization Medicine 10(3): 195-0, 2009

Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Circulation Journal 72(5): 825-831, 2008

Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension. Journal of Medical Ultrasonics 41(2): 173-180, 2014